Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Genzyme's Virus Problems | Main | One. . .Billion. . .Dollars! »

June 22, 2009

Funky Carbocycles

Email This Entry

Posted by Derek

Earlier this month I posted about rolofylline, which I noted has a rather unusual noradamantane attached to it. Now check out this ORL-1 compound from Banyu, complete with the not-so-widely-heard-of bicycloheptane-spirocyclopropane group.

This was not arrived at lightly, as you'd imagine. There's a table in the Supporting information for the paper, but I'll quote from the body of the main manuscript:

Various kinds of cycloalkanes, substituted or nonsubstituted cyclopropyl rings to medium sized rings (such as cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclononylmethyl, cyclodecylmethyl), spiroalkane (such as spiro[2.5]octanemethyl, spiro[3.5]nonanemethyl, spiro[4.5]decanemethyl, spiro[2.4]heptanemethyl, spiro[3.4]octanemethyl, spiro[4.4]nonanemethyl), bicycloheptane (such as methylbicyclo[2.2.1]heptylmethyl, dimethylbicyclo[2.2.1]heptylmethyl, spirocyclopropanebicycloheptanemethyl), and branched alkanes (such as 3,3-dimethylbutane, 3,3-dithylbutane, 1-methylcyclobutaneethyl, 1-methylcyclopentaneethyl, 1-methylcyclohexaneethyl) were tested.

No, that couldn't have been a lot of fun. Anyone else out there found themselves having to optimize grease recently?

Comments (5) + TrackBacks (0) | Category: Drug Development | Life in the Drug Labs


COMMENTS

1. Igor on June 22, 2009 10:20 AM writes...

Sadly it seems that many of us in med chem tend to spend way too much time optimizing grease.

I have never worked in the CNS area, but it appears to me that many of the successful modulators are of the small MW variety with some grease, a tertiary basic group, and some other spinach.

So, it appears that many times the space available for novelty becomes some new variant of the greasy portion, although I have seem some pretty funky piperidine/piperazine surrogates. I would expect the Banyu guys may have just killed two birds with one stone in this case, activity and patentability.

Derek, since you have some experience in this area, are my observations correct or skewed?

Permalink to Comment

2. Norepi on June 22, 2009 4:11 PM writes...

It seems that another place grease optimization comes up is in some of the steroid mimics that inhibit the various metabolic steroid-processing enzymes (where there are large hydrophobic cavities). I remember Merck's candidate (I believe it was called Compound 544), for inhibition of 11-beta hydroxysteroid dehydrogenase was one of a large class of adamantyl triazoles They arrived at this structure after going through a long series of bulkier carbocycles and various things like cyclooctane, with adamantyl becoming a case of The Only Thing That Works There.

Permalink to Comment

3. Zak on June 22, 2009 7:42 PM writes...

Wonder if the fact that they are both from Japan is relevant?

Permalink to Comment

4. drug_hunter on June 22, 2009 9:27 PM writes...

There seems to be something about unusual aliphatic polycyclic hydrocarbons - they are sometimes far more stable to metabolic oxidation than I would have guessed they'd be. I haven't seen any good explanation for the "rules" that govern this behavior - anyone have any good references or ideas?

Permalink to Comment

5. chupvl on July 16, 2009 4:21 AM writes...

the question is to fill the grease gap or fill the binding site tightly? The structure of ORL1 can be modeled but not discussed in the article (pity).

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Google's Nanoparticle Diagnostic Ideas
Aileron Heads Toward the Clinic
Viehbacher Out at Sanofi
Rumblings About AstraZeneca and Antibiotics
Amgen Cuts Harder
An Open-Source Cancer Pitch, Deconstructed
Sanofi - Trouble At the Top?
Sarepta's Duchenne Therapy Is A Lot Further Away